Compare DAO & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | ABCL |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2019 | 2020 |
| Metric | DAO | ABCL |
|---|---|---|
| Price | $12.08 | $5.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.40 |
| AVG Volume (30 Days) | 89.3K | ★ 8.1M |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $12.24 | N/A |
| Revenue Next Year | $14.60 | $21.85 |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $8.00 | $2.75 |
| 52 Week High | $13.04 | $6.79 |
| Indicator | DAO | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 51.46 |
| Support Level | $9.20 | $3.42 |
| Resistance Level | $13.01 | $5.63 |
| Average True Range (ATR) | 1.23 | 0.61 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 68.15 | 45.07 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.